Gene polymorphisms as risk factors for predicting the cardiovascular manifestations in Marfan syndrome

Summary

Folic acid metabolism enzyme polymorphisms are believed to be responsible for the elevation of homocysteine (HCY) concentration in the blood plasma, correlating with the pathogenesis of aortic aneurysms and aortic dissection. We studied 71 Marfan patients divided into groups based on the severity of cardiovascular involvement: no intervention required (n=27, Group A); mild involvement requiring intervention (n=17, Group B); severe involvement (n=27, Group C) subdivided into aortic dilatation (n=14, Group C1) and aortic dissection (n=13, Group C2), as well as 117 control subjects. We evaluated HCY, folate, vitamin B12 and the polymorphisms of methylenetetrahydrofo-late reductase (MTHFR;c.665C>T and c.1286A>C), methionine synthase (MTR;c.2756A>G) and methionine synthase reductase (MTRR;c.66A>G). Multiple comparisons showed significantly higher levels of HCY in Group C2 compared to Groups A, B, C1 and control group (p< 0.0001, p< 0.0001, p=0.001 and p=0.003, respectively). Fo-late was lower in Group C2 than in Groups A, B, C1 and control subjects (p< 0.0001, p=0.02, p< 0.0001 and p< 0.0001, respectively). Group C2 had the highest prevalence of homozygotes for all four gene polymorphisms. Multivariate logistic regression analysis revealed that HCY plasma level was an independent risk factor for severe cardiovascular involvement (Group C; odds ratio [OR] 1.85, 95 % confidence interval [CI] 1.28–2.67, p=0.001) as well as for aortic dissection (Group C2; OR 2.49, 95 %CI 1.30–4.78, p=0.006). In conclusion, severe cardiovascular involvement in Marfan patients, and especially aortic dissection, is associated with higher HCY plasma levels and prevalence of homozygous genotypes of folic acid metabolism enzymes than mild or no cardiovascular involvement. These results suggest that impaired folic acid metabolism has an important role in the development and remodelling of the extracellular matrix of the aorta.

Keywords

Cardiology - vascular remodelling - single nucleotide polymorphism - HCY - matrix-metalloproteinases

^* These authors contributed equally to study.

• References

• 1 Gao LG, Luo F, Hui RT. et al. Recent molecular biological progress in Marfan syndrome and Marfan-associated disorders. Ageing Res Rev 2010; 9: 363-368.
• 2 Gelb BD. Marfan’s syndrome and related disorders--more tightly connected than we thought. N Engl J Med 2006; 355: 841-844.
• 3 Grover M, Brunetti-Pierri N, Belmont J. et al. Assessment of bone mineral status in children with Marfan syndrome. Am J Med Genet A 2012; 158A: 2221-2224.
• 4 Benke K, Agg B, Szilveszter B. et al. The role of transforming growth factor-beta in Marfan syndrome. Cardiol J 2013; 20: 227-234.
• 5 Agg B, Benke K, Szilveszter B. et al. Possible extracardiac predictors of aortic dissection in Marfan syndrome. BMC Cardiovasc Disord 2014; 14: 47.
• 6 Franken R, Heesterbeek V T de Waard. et al. Diagnosis and genetics of Marfan syndrome. Expert opinion on orphan drugs. October 2014; 2: 1049-1062.
• 7 Robinson PN, Godfrey M. The molecular genetics of Marfan syndrome and related microfibrillopathies. J Med Genet 2000; 37: 9-25.
• 8 Brunelli T, Prisco D, Fedi S. et al. High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm. J Vasc Surg 2000; 32: 531-536.
• 9 Krumdieck CL, Prince CW. Mechanisms of homocysteine toxicity on connective tissues: implications for the morbidity of aging. J Nutr 2000; 130 2S 365S-368S.
• 10 Hubmacher D, Tiedemann K, Bartels R. et al. Modification of the structure and function of fibrillin-1 by homocysteine suggests a potential pathogenetic mechanism in homocystinuria. J Biol Chem 2005; 280: 34946-34955.
• 11 Zhou D, Mei Q, Luo H. et al. The polymorphisms in methylenetetrahydrofolate reductase, methionine synthase, methionine synthase reductase, and the risk of colorectal cancer. Int J Biol Sci 2012; 8: 819-830.
• 12 Kang SS, Wong PW, Susmano A. et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536-545.
• 13 Weisberg I, Tran P, Christensen B. et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172.
• 14 Leclerc D, Campeau E, Goyette P. et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996; 5: 1867-1874.
• 15 Gaughan DJ, Kluijtmans LA, Barbaux S. et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001; 157: 451-456.
• 16 Debette S, Markus HS. The genetics of cervical artery dissection: a systematic review. Stroke 2009; 40: e459-466.
• 17 Giusti B, Porciani MC, Brunelli T. et al. Phenotypic variability of cardiovascular manifestations in Marfan Syndrome. Possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism. Eur Heart J 2003; 24: 2038-2045.
• 18 Sbarouni E, Georgiadou P, Analitis A. et al. High homocysteine and low folate concentrations in acute aortic dissection. Int J Cardiol 2013; 168: 463-466.
• 19 Agota A, Agg B, Benke K. et al. The establishment of the Marfan syndrome bio-bank in Hungary – Erratum. Orv Hetil 2012; 153: 600.
• 20 Loeys BL, Dietz HC, Braverman AC. et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010; 47: 476-485.
• 21 Shimizu H, Kasahara H, Nemoto A. et al. Can early aortic root surgery prevent further aortic dissection in Marfan syndrome?. Interact Cardiovasc Thorac Surg 2012; 14: 171-175.
• 22 Song HK, Kindem M, Bavaria JE. et al. Long-term implications of emergency versus elective proximal aortic surgery in patients with Marfan syndrome in the Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions Consortium Registry. J Thorac Cardiovasc Surg 2012; 143: 282-286.
• 23 Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Vahanian A, Alfieri O, Andreotti F. et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451-2496.
• 24 Treasure T, Takkenberg JJ, Pepper J. Surgical management of aortic root disease in Marfan syndrome and other congenital disorders associated with aortic root aneurysms. Heart 2014; 100: 1571-1576.
• 25 Bottiglieri T, Parnetti L, Arning E. et al. Plasma total homocysteine levels and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene: a study in an Italian population with dementia. Mechan Age Develop 2001; 122: 2013-2023.
• 26 Judge DP, Dietz HC. Marfan’s syndrome. Lancet 2005; 366: 1965-1976.
• 27 Doronzo G, Russo I, attiello L. et al. Homocysteine rapidly increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells. Role of phosphatidyl inositol 3-kinase and mitogen activated protein kinase pathways. Thromb Haemost 2005; 94: 1285-1293.
• 28 Ikonomidis JS, Jones JA, Barbour JR. et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation 2006; 114 (Suppl. 01) I365-370.
• 29 Raaf L, Noll C, Cherifi Mel. et al. Myocardial fibrosis and TGFB expression in hyperhomocysteinemic rats. Mol Cell Biochem 2011; 347: 63-70.
• 30 Neptune ER, Frischmeyer PA, Arking DE. et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003; 33: 407-411.
• 31 Chung AW, Au Yeung K, Sandor GG. et al. Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and –9 in the thoracic aortic aneurysm in Marfan syndrome. Circ Res 2007; 101: 512-522.
• 32 Hubmacher D, Cirulis JT, Miao M. et al. Functional consequences of homocysteinylation of the elastic fiber proteins fibrillin-1 and tropoelastin. J Biol Chem 2010; 285: 1188-1198.
• 33 Selamet Tierney ES, Levine JC, Chen S. et al. Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome. J Am Soc Echocardiogr 2013; 26: 657-666.
• 34 McLoughlin D, McGuinness J, Byrne J. et al. Pravastatin reduces Marfan aortic dilation. Circulation 2011; 124 (Suppl. 11) S168-173.
• 35 Brooke BS, Habashi JP, Judge DP. et al. Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med 2008; 358: 2787-2795.